# Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

> **NCT01309126** · PHASE3 · TERMINATED · sponsor: **HiberCell, Inc.** · enrollment: 217 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Imprime PGG + cetuximab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01309126
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2017-02
- **Final completion:** 2017-02
- **Target enrollment:** 217 (ACTUAL)
- **Why stopped:** Due to enrollment challenges resulting from changing treatment patterns in the use of cetuximab, the study has been terminated. No patients remain on study.
- **Last updated:** 2017-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309126, "Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01309126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*